Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
1. A method of treating inflammation in a patient in need thereof, comprising administering an effective amount of an antagonist of IL-23 and IL-17A or IL-17F to the patient, wherein the antagonist comprises an anti-IL-23 antibody or fragment thereof, which binds the p19 subunit of IL-23, and comprises a heavy chain variable region polypeptide as shown in SEQ ID NO:268 and a light chain variable region polypeptide as shown in SEQ ID NO:266; and a cross-reactive antibody or fragment thereof, which binds IL-17A or IL-17F, and comprises the CDRs of an antibody selected from the group consisting of:
a) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7987;
b) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7988; and
c) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7989.
2. The method of claim 1 , wherein the cross-reactive antibody or fragment thereof comprises heavy chain variable region polypeptide selected from the group consisting of:
a. the heavy chain variable region of the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7987;
b. the heavy chain variable region of the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7988; and
c. the heavy chain variable region of the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7989.
3. The method of claim 1 , wherein the cross-reactive antibody or fragment thereof comprises a light chain variable region polypeptide selected from the group consisting of:
a. the light chain variable region of the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7987;
b. the light chain variable region of the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7988; and
c. the light chain variable region of the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7989.
4. The method of claim 1 , wherein the cross-reactive antibody or fragment thereof comprises a heavy chain variable region polypeptide and a light chain variable region polypeptide of the antibody selected from the group consisting of:
a) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7987;
b) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7988; and
c) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7989.
5. The method of claim 1 , wherein said cross-reactive antibody or fragment thereof is humanized.
6. The method of claim 1 , wherein said cross-reactive antibody or fragment thereof is chimeric.
7. The method of claim 1 , wherein the cross-reactive antibody or fragment thereof is a single chain antibody.
8. The method of claim 1 , wherein the anti-IL-23 antibody or fragment thereof is a single chain antibody.
9. The method of claim 1 , wherein the anti-IL-23 antibody fragment is selected from the group consisting of Fv, Fab, Fab′, F(ab) 2 , and F(ab′) 2 , and wherein the cross-reactive antibody fragment is selected from the group consisting of Fv, Fab, Fab′, F(ab) 2 , and F(ab′) 2 .
10. The method of claim 1 , wherein the antagonist is a bispecific antibody.
11. The method of antagonist of claim 10 , wherein the antibody is a tascFv, a biscFv, or a BiAb antibody.
12. The method of claim 1 , wherein the antagonist comprises a PEG moiety.
13. The method of claim 1 , wherein the antagonist comprises an Fc moiety.
14. The method of claim 1 , wherein the antagonist is a bivalent, trivalent, or tetravalent antibody.